EVAXION BIOTECH ($EVAX) posted quarterly earnings results for Q3 2026 on Thursday, November 19th. The company reported earnings of -$0.50 per share, missing estimates of -$0.44 by $0.06. The company also reported revenue of $0, equaling estimates of $0 by $0.
You can see Quiver Quantitative's $EVAX stock page to track data on insider trading, hedge fund activity, congressional trading, and more.
EVAXION BIOTECH Hedge Fund Activity
We have seen 6 institutional investors add shares of EVAXION BIOTECH stock to their portfolio, and 9 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- TWO SIGMA INVESTMENTS, LP added 15,227 shares (+inf%) to their portfolio in Q3 2026, for an estimated $49,944
- XTX TOPCO LTD removed 12,899 shares (-100.0%) from their portfolio in Q3 2026, for an estimated $42,308
- RENAISSANCE TECHNOLOGIES LLC added 12,400 shares (+36.7%) to their portfolio in Q3 2026, for an estimated $40,672
- STRATOS WEALTH PARTNERS, LTD. added 10,984 shares (+inf%) to their portfolio in Q3 2026, for an estimated $36,027
- UBS GROUP AG removed 5,338 shares (-85.1%) from their portfolio in Q3 2026, for an estimated $17,508
- CITADEL ADVISORS LLC removed 5,140 shares (-14.0%) from their portfolio in Q3 2026, for an estimated $16,859
- SMARTHARVEST PORTFOLIOS, LLC added 4,502 shares (+33.4%) to their portfolio in Q3 2026, for an estimated $14,766
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
Check out the Quiver Quantitative API to build on top of data on congressional stock trading, insider transactions, hedge fund moves, and more.